Drug intelligence / Profile preview

TEV-333

Development stage: Preclinical
Lead developer: Teva Pharmaceutical Industries

Overview

TEV-333 is a biosimilar candidate being developed for multiple oncology indications. Under a strategic licensing agreement, mAbxience is responsible for its development and production, while Teva handles the regulatory processes and commercialization in markets including Europe and the U.S. As a biosimilar, its mechanism of action is expected to be identical to its unnamed reference product.

Beyond the preview

Go deeper on TEV-333.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TEV-333.

Explore the full profile